Frontiers in Microbiology (Oct 2022)

Complete genome sequencing and in silico genome mining reveal the promising metabolic potential in Streptomyces strain CS-7

  • Khorshed Alam,
  • Jinfang Hao,
  • Lin Zhong,
  • Guoqing Fan,
  • Qing Ouyang,
  • Md. Mahmudul Islam,
  • Saiful Islam,
  • Hongluan Sun,
  • Youming Zhang,
  • Youming Zhang,
  • Ruijuan Li,
  • Aiying Li

DOI
https://doi.org/10.3389/fmicb.2022.939919
Journal volume & issue
Vol. 13

Abstract

Read online

Gram-positive Streptomyces bacteria can produce valuable secondary metabolites. Streptomyces genomes include huge unknown silent natural product (NP) biosynthetic gene clusters (BGCs), making them a potential drug discovery repository. To collect antibiotic-producing bacteria from unexplored areas, we identified Streptomyces sp. CS-7 from mountain soil samples in Changsha, P.R. China, which showed strong antibacterial activity. Complete genome sequencing and prediction in silico revealed that its 8.4 Mbp genome contains a total of 36 BGCs for NPs. We purified two important antibiotics from this strain, which were structurally elucidated to be mayamycin and mayamycin B active against Staphylococcus aureus. We identified functionally a BGC for the biosynthesis of these two compounds by BGC direct cloning and heterologous expression in Streptomyces albus. The data here supported this Streptomyces species, especially from unexplored habitats, having a high potential for new NPs.

Keywords